logo
Share SHARE
FONT-SIZE Plus   Neg

Reports: Watson Pharma Close To Buying Actavis In A $7 Bln Deal

Generic drugmaker Watson Pharmaceuticals, Inc. Co. (WPI) is reportedly close to acquiring privately-held European peer Actavis for about $7 billion. The news sent Watson's shares soaring, which closed higher by nearly 9 percent.

The Swiss firm was taken private in 2007 and Icelandic business tycoon Bjorgolfur Thor Bjorgolfsson has a 78 percent stake in the company.

Parsippany, New Jersey-based Watson's offerings include generic version of cholesterol drug Lipitor and Concerta, intended for attention deficit hyperactivity disorder. The company last month reported a surge in profit for the fourth quarter mainly on strong sales of these two drugs.

Actavis also has a business nearly as big as that of Watson and has a formidable presence in central and eastern Europe. It has around 830 products on the market and about 350 products under development and pending registration. The U.S. company may pay 5.0 billion euros to 5.5 billion euros for the Swiss firm.

Among its previous acquisitions, Watson purchased Andrx Corp in 2006 for $1.9 billion and bought Arrow Group for $1.75 billion in 2009. The company last year acquired Specifar Pharmaceuticals of Greece for $562 million.

WPI climbed $5.16 or 8.82 percent on Wednesday to close the session at $63.69 on a volume of 10.86 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Senate Republicans appear poised to approve a budget resolution that will serve as the legislative vehicle for their tax reform plan. The non-binding budget resolution unlocks the reconciliation process, allowing Republicans to pass their tax reform plan with a simple 51-vote majority in the Senate. President Donald Trump intends to nominate antitrust attorney Joseph Simons as chairman of the Federal Trade Commission, the White House announced on Thursday. Simons, who served as an FTC official under President George W. Bush, is currently a partner and co-chair of the antitrust group at law firm Paul Weiss. Less than four months after its debut on the New York Stock Exchange, Blue Apron Holdings Inc. said it is laying off 6 percent of its workforce. In a regulatory filing on Wednesday, the embattled meal-kit delivery company said it has implemented a company-wide realignment of personnel to support its strategic priorities.
comments powered by Disqus
Follow RTT